临床试验阶段抗HBV新药的研究现状

李强; 黄玉仙; 陈良

doi:10.3969/j.issn.1001-5256.2016.02.038

临床试验阶段抗HBV新药的研究现状

DOI: 10.3969/j.issn.1001-5256.2016.02.038

复旦大学附属公共卫生临床中心肝炎一科

基金项目:

上海市科委“科技创新行动计划”医学与农业领域重点项目(13401902100)；上海市卫生局临床医学应用研究项目(20114279)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2374
- HTML全文浏览量: 7
- PDF下载量: 577
- 被引次数: 0
出版历程
- 收稿日期: 2015-07-29
- 出版日期: 2016-02-20

Current studies of novel drugs against hepatitis B virus in clinical trials

First Department of Hepatitis,Public Health Clinical Center Affiliated to Fudan University

Research funding:

摘要

摘要: 慢性乙型肝炎（CHB）是肝硬化和肝癌的常见病因之一。干扰素与核苷和核苷酸类药物能够有效控制病情,但HBs Ag清除率或血清学转换率极低,大多数患者会在停药后复发。近年来,随着HBV-宿主相互作用机制研究的不断深入,产生了许多有望成功治愈CHB的新药。综述了处于临床试验Ⅰ、Ⅱ、Ⅲ阶段的抗HBV新药,认为抗HBV新药已初步显示出令人欣喜的前景。
- 肝炎病毒,乙型 /
- 抗病毒药 /
- 临床试验 /
- 综述
Abstract: Chronic hepatitis B( CHB) is one of the major causes of liver cirrhosis and hepatocellular carcinoma. Interferon and nucleos( t)ide analogues can control disease progression. However,they cause very low HBs Ag clearance or seroconversion rates and relapse in most patients after treatment withdrawal. In recent years,the further understanding of the interaction between hepatitis B virus( HBV) and host gives birth to a large number of novel drugs that hold promise for successful cure of CHB. This paper reviews several novel drugs against HBV in phase Ⅰ,Ⅱ,or Ⅲ clinical trials,and points out that these novel drugs against HBV have preliminarily indicated a bright future.
- hepatitis B virus /
- antiviral agents /
- clinical trial /
- review

HTML全文

参考文献(37)

[1]European Association for The Study of The Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[2]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int,2015,35(Suppl 1):78-81.

[3]KAO JH.HBeA g-positive chronic hepatitis B:why do I treat my patients with pegylated interferon?[J].Liver Int,2014,34(1):112-119.

[4]BUTI M.HBeA g-positive chronic hepatitis B:why do i treat my patients with nucleos(t)ide analogs?[J].Liver Int,2014,34(1):108-111.

[5]BAM RA,YANT SR,CIHLAR T.Tenofovir alafenamide is not a substrate for renal organic anion transporters(OATs)and does not exhibit OAT-dependent cytotoxicity[J].Antivir Ther,2014,19(7):687-692.

[6] AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty eight day safety and efficacy of tenofovir alafenamide(TAF)fumarate in chronic hepatitis B(CHB)patients[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.

[7]AGARWAL K,FUNG SK,NGUYEN TT,et al.Twenty-eight day safety,antiviral activity,and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection[J].J Hepatol,2015,62(3):533-540.

[8]YUEN MF,KIM J,KIM CR,et al.A randomized placebo-controlled,dose-finding study of oral LB80380 in HBeA g-positive patients with chronic hepatitis B[J].Antivir Ther,2006,11(8):977-983.

[9]LAI CL,AHN SH,LEE KS,et al.Phase IIb multicentred randomised trial of besifovir(LB80380)versus entecavir in Asian patients with chronic hepatitis B[J].Gut,2014,63(6):996-1004.

[10]YUEN MF,AHN SH,LEE KS,et al.Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs.entecavir:results from a multicentre study[J].J Hepatol,2015,62(3):526-532.

[11]JIANG M,BROERING R,TRIPPLER M,et al.Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J].J Viral Hepat,2014,21(12):860-872.

[12]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.

[13]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,54(6):426-432.

[14]XU DZ,WANG XY,SHEN XL,et al.Results of a phaseⅢclinical trial with an HBsA g-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients:experiences and findings[J].J Hepatol,2013,59(3):450-456.

[15]VOLZ T,ALLWEISS L,BEN MM,et al.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J].J Hepatol,2013,58(5):861-867.

[16]HAEFELI WE,BLANK,MIKUS G,et al.Successful first administration of Myrcludex B,a first-in-class Hepatitis B and D Virus entry inhibitor,in humans[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.

[17]BOGOMOLOV P,VORONKOVA N,ALLWEISS L,et al.A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.

[18]BREZILLON N,BRUNELLE MN,MASSINET H,et al.Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Albu PA/SCID mice[J].PLoS One,2011,6(12):e25096.

[19]WU G,LIU B,ZHANG Y,et al.Preclinical characterization of GLS4,an inhibitor of hepatitis B virus core particle assembly[J].Antimicrob Agents Chemother,2013,57(11):5344-5354.

[20]WANG XY,WEI ZM,WU GY,et al.In vitro inhibition of HBV replication by a novel compound,GLS4,and its efficacy against adefovirdipivoxil-resistant HBV mutations[J].Antivir Ther,2012,17(5):793-803.

[21]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that can rapidly restore immunocompetence in patients with chronic hepatitis B[C]//61st annual meeting of the American Association for the Study of Liver Diseases.Boston,MA,2010.

[22]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a potent HBsA g release inhibitor that elicits durable immunological control of chronic HBV infection[C]//62nd annual meeting of the American Association for the Study of Liver Diseases(AASLD).San Francisco,CA,2011.

[23]MAHTAB MA,BAZINET M,VAILLANT A.REP 9AC:a second generation HBsA g release inhibitor with improved tolerability[C]//63rd annual meeting of the American Association for the Study of Liver Diseases(AASLD).Boston,MA,2012.

[24]WOODDELL CI,ROZEMA DB,HOSSBACH M,et al.Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection[J].Mol Ther,2013,21(5):973-985.

[25]YUEN MF,CHAN H,GIVEN B,et al.PhaseⅡ,dose ranging study of ARC-520,a siRNA-based therapeutic,in patients with chronic hepatitis B virus infection[C]//49th annual meeting of the European Association for the Study of the Liver(EASL).Britain,2014.

[26]SEIGAL BA,CONNORS WH,FRALEY A,et al.The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library,and their optimization to give lead compounds with in vivo antitumor activity[J].J Med Chem,2015,58(6):2855-2861.

[27]EBERT G,ALLISON C,PRESTON S,et al.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J].Proc Natl Acad Sci U S A,2015,112(18):5803-5808.

[28]GAGGAR A,COESHOTT C,APELIAN D,et al.Safety,tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study[J].Vaccine,2014,32(39):4925-4931.

[29]REN XW,XU WR,ZOU MX,et al.A Compound elvucitabine pharmaceutical composition and its preparation method and uses:CN102652748A[P].2012-09-05.(in Chinese)任晓文,徐为人,邹美香,等.稳定的艾夫他滨药物组合物及其制备方法:CN102652748A[P].2012-09-05.

[30] LIM SG,LEE KS,CHUANG WL,et al.Safety and antiviral activity of pradefovir in patients with chronic hepatitis B virus infection:48 week analysis of a phase 2 study[J].J Clin Virol,2006,36(2):231-238.

[31]REDDY KR,MATELICH MC,UGARKAR BG,et al.Pradefovir:a prodrug that targets adefovir to the liver for the treatment of hepatitis B[J].J Med Chem,2008,51(3):666-676.

[32]IYER RK,MARQUIS J,HARTER M,et al.Preclinical studies of SB9200 for hepatitis treatment[C]//34th annual meeting of the American College of Toxicology.San Antonio,TX,2014.

[33]CUNNINGHAM ME,WRIGHT JD,PANDEY RK,et al.Pan-genotypic anti-HCV activity of SB 9200 assessed in the'capture-fusion'replication assay[C]//64th annual meeting and postgraduate course of the American Association for the Study of Liver Diseases.Washington,DC,2013.

[34] SPELLMAN M,MARTIN JT.Treament of chronic hepatitis B infection with DV-601,a therapeutic vaccine[C]//46th annual meeting of the European Association for the Study of the Liver(EASL).Berlin,2011.

[35]FELD JJ,COLLEDGE D,SOZZI V,et al.The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging[J].Antiviral Res,2007,76(2):168-177.

[36]BENGSCH B,MARTIN B,THIMME R.Restoration of HBV-specific CD8+T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation[J].J Hepatol,2014,61(6):1212-1219.

[37]SHERMAN AC,TREHANPATI N,DAUCHER M,et al.Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir[J].AIDS Res Hum Retroviruses,2013,29(4):665-672.

施引文献

资源附件(0)

访问统计